Prognosis and Course of COVID-19 Infection in Hospitalised Patients
1 other identifier
observational
345
1 country
2
Brief Summary
The aim of the cohort prospective observational study is to define the major factors influencing the course of COVID-19 infections and its prognosis in hospitalised patients. The investigators plan to include 300 patients hospitalised with COVID-19 infection. The phone contacts with patients are due after 90 and 180 days after discharge.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2020
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2020
CompletedFirst Submitted
Initial submission to the registry
February 9, 2021
CompletedFirst Posted
Study publicly available on registry
February 12, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 10, 2023
CompletedJanuary 26, 2023
January 1, 2023
4 months
February 9, 2021
January 24, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Need in biological therapy or/and respiratory support
The primary endpoint is the need in biological therapy or/and respiratory support including noninvasive ventilation during hospital stay
Up to 1 month
Secondary Outcomes (3)
Number of days spent in hospital
Up to 1 month
All-cause death
90 days
All-cause death
180 days
Interventions
The chitotriosidase activity will be measured in all the subjects
Eligibility Criteria
300 patients hospitalised with COVID-19 infection
You may qualify if:
- Hospitalisation with COVID-19
You may not qualify if:
- History of hospitalisation with COVID-19 infection
- Discharge from the hospital before the end of the treatment course
- Transfer to another hospital
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
University Hospital #1
Moscow, Russia
University Hospital #4
Moscow, Russia
Related Publications (1)
Schelkanovtseva ES, Isaev GO, Mironova OY, Balakhonov AA, Skvortsov AV, Nagornov IO, Suvorov AY, Fomin VV, Panferov AS. [The survival prediction of hospitalized patients with COVID-19: the role of chitotriosidase level in peripheral blood]. Ter Arkh. 2023 Sep 29;95(7):543-547. doi: 10.26442/00403660.2023.07.202280. Russian.
PMID: 38159003DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Olga Mironova, PhD
Sechenov University
- STUDY CHAIR
Ekaterina Schelkanovtseva, MD
Sechenov University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
February 9, 2021
First Posted
February 12, 2021
Study Start
November 1, 2020
Primary Completion
March 1, 2021
Study Completion
January 10, 2023
Last Updated
January 26, 2023
Record last verified: 2023-01